Lenacapavir for HIV PrEP: Narrative Review of Clinical Trials and Implications for Patient Access

• DOI: 10.1007/s40506-024-00281-2
• Publication Date: 2025-01-09T06:59:22Z
• Authors: Swarnali Goswami; Sai Veeramachaneni; Prajakta P. Masurkar
• Keywords: Pre-exposure prophylaxis

Abstract Purpose of Review By the end 2023, approximately 39.9 million people worldwide were living with HIV, including 1.2 in United States. Although treatment advancements have improved health outcomes, HIV continues to pose significant challenges, particularly among key populations like men who sex (MSM), transgender women, and cisgender women. Pre-exposure prophylaxis (PrEP) has emerged as an effective strategy lower risk transmission, but daily oral regimens often face adherence difficulties. This narrative review aims summarize effectiveness safety Lenacapavir, latest long-acting injectable PrEP currently under clinical trials. Recent Findings a novel bi-annual dosing, offers advantages terms privacy, potentially reducing stigma associated medication. summarizes preventing profile strategies being explored overcome barriers access. Compared traditional options, lenacapavir shown remarkable efficacy recent trials, two different Phase 3 studies where it achieved 100% prevention rate women 96% men, gender non-binary individuals. Summary Lenacapavir holds promise transformative option prevention. However, continued research development improve access are essential meet public objectives ultimately epidemic by 2030.